AR002280A1 - A COMPOUND DERIVED FROM THE POLY-PIRROL-CARBOXAMIDONAPHTHALENIC ACID, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND A PROCEDURE TO IMPROVE THE SYSTEMIC BIOAVAILABILITY OF A BIOLOGICALLY ACTIVE COMPOUND. - Google Patents

A COMPOUND DERIVED FROM THE POLY-PIRROL-CARBOXAMIDONAPHTHALENIC ACID, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND A PROCEDURE TO IMPROVE THE SYSTEMIC BIOAVAILABILITY OF A BIOLOGICALLY ACTIVE COMPOUND.

Info

Publication number
AR002280A1
AR002280A1 ARP960101576A AR10157696A AR002280A1 AR 002280 A1 AR002280 A1 AR 002280A1 AR P960101576 A ARP960101576 A AR P960101576A AR 10157696 A AR10157696 A AR 10157696A AR 002280 A1 AR002280 A1 AR 002280A1
Authority
AR
Argentina
Prior art keywords
procedure
biologically active
acid
poly
active compound
Prior art date
Application number
ARP960101576A
Other languages
Spanish (es)
Inventor
Nicola Mongelli
Giovanni Biasoli
Borgia Andrea Lombardi
Ciomei
Original Assignee
Pharmacia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Spa filed Critical Pharmacia Spa
Publication of AR002280A1 publication Critical patent/AR002280A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Se provee un compuesto derivado del ácido ácido-poli-pirrol-carboxamidonaftalénico de fórmula (II); en donde R es ungrupo ácido; m es un entero de 1 a 3; n es cero o un entero de 1 a 3; A es un espaciador enzimáticamente hidrolizable; y X es un compuesto biológicamenteactivo; o una sal farmacéuticamente aceptable del mismo, para usar como un agente antiproliferativo, en particular antitumoral y antiangiogénico y como unagente antiinflamatorio. Además se provee un procedimiento para su preparación, una composición farmacéutica que lo contiene y un procedimiento para mejorarla biodisponibilidad sistémica de un compuesto X biológicamente activo.Provided is a compound derived from poly-pyrrole-carboxamidonaphthalene acid of formula (II); where R is an acid group; m is an integer from 1 to 3; n is zero or an integer from 1 to 3; A is an enzymatically hydrolyzable spacer; and X is a biologically active compound; or a pharmaceutically acceptable salt thereof, for use as an antiproliferative agent, in particular antitumor and antiangiogenic and as an anti-inflammatory agent. Furthermore, a process for its preparation, a pharmaceutical composition containing it and a process for improving the systemic bioavailability of a biologically active compound X is provided.

ARP960101576A 1995-03-01 1996-02-29 A COMPOUND DERIVED FROM THE POLY-PIRROL-CARBOXAMIDONAPHTHALENIC ACID, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND A PROCEDURE TO IMPROVE THE SYSTEMIC BIOAVAILABILITY OF A BIOLOGICALLY ACTIVE COMPOUND. AR002280A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9504065.5A GB9504065D0 (en) 1995-03-01 1995-03-01 Poly-pyrrolecarboxamidonaphthalenic acid derivatives

Publications (1)

Publication Number Publication Date
AR002280A1 true AR002280A1 (en) 1998-03-11

Family

ID=10770421

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101576A AR002280A1 (en) 1995-03-01 1996-02-29 A COMPOUND DERIVED FROM THE POLY-PIRROL-CARBOXAMIDONAPHTHALENIC ACID, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND A PROCEDURE TO IMPROVE THE SYSTEMIC BIOAVAILABILITY OF A BIOLOGICALLY ACTIVE COMPOUND.

Country Status (18)

Country Link
EP (1) EP0758339A1 (en)
JP (1) JPH10504319A (en)
KR (1) KR970702868A (en)
CN (1) CN1148391A (en)
AR (1) AR002280A1 (en)
AU (1) AU696470B2 (en)
CA (1) CA2189358A1 (en)
EA (1) EA000006B1 (en)
FI (1) FI964331A (en)
GB (1) GB9504065D0 (en)
HU (1) HUP9603305A3 (en)
IL (1) IL117193A0 (en)
MX (1) MX9605089A (en)
NO (1) NO964610D0 (en)
NZ (1) NZ302267A (en)
PL (1) PL317094A1 (en)
WO (1) WO1996026950A1 (en)
ZA (1) ZA961636B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4459297A (en) * 1996-09-30 1998-04-24 Bayer Aktiengesellschaft Glycoconjugates from modified camptothecin derivates (20-o-linkage)
DE19640969A1 (en) * 1996-10-04 1998-04-16 Bayer Ag 20-0 linked glycoconjugates from camptothecin
ID23424A (en) * 1997-05-14 2000-04-20 Bayer Ag GLIKOKONJUGUS OF 20 (S) -CAMPTOTESIN
GB9713733D0 (en) * 1997-06-27 1997-09-03 Pharmacia & Upjohn Spa Poly-branched polycarboxamido compounds
GB9713732D0 (en) * 1997-06-27 1997-09-03 Pharmacia & Upjohn Spa Substituted triazinic compounds
US6485514B1 (en) 1997-12-12 2002-11-26 Supergen, Inc. Local delivery of therapeutic agents
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
EP1401817A4 (en) 2001-06-13 2005-11-02 Genesoft Pharmaceuticals Inc Isoquinoline compounds having antiinfective activity
AU2003249641B2 (en) * 2002-05-16 2009-08-20 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
WO2003101998A1 (en) 2002-06-03 2003-12-11 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
AU2003258022A1 (en) 2002-08-02 2004-02-23 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
US7265129B2 (en) 2002-10-25 2007-09-04 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
EP1587529A4 (en) 2002-12-10 2009-08-12 Oscient Pharmaceuticals Corp Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif
PT2264043T (en) 2005-09-02 2018-01-19 Glycomimetics Inc Heterobifunctional pan-selectin inhibitors
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
WO2011163572A2 (en) * 2010-06-24 2011-12-29 University Of Kansas Bifunctional conjugate compositions and associated methods
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
PT2794626T (en) 2011-12-22 2018-01-12 Glycomimetics Inc E-selectin antagonist compounds
SI2928476T1 (en) 2012-12-07 2018-06-29 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
HUE045542T2 (en) 2014-12-03 2019-12-30 Glycomimetics Inc Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
CA3009836A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
KR102653723B1 (en) 2016-10-07 2024-04-01 글리코미메틱스, 인크. Highly potent multimeric e-selectin antagonists
US11197877B2 (en) 2017-03-15 2021-12-14 Glycomimetics. Inc. Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
EP3381897A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Derivatives of the disodium 2,2'-{carbonylbis[imino-3,1-phenylenecarbonylimino(1-methyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalene-1,5-disulfonate salt and related compounds as heparanase inhibitors for the treatment of cancer
EP3717013A1 (en) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
WO2019133878A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
JP7455064B2 (en) 2018-03-05 2024-03-25 グリコミメティクス， インコーポレイテッド Methods of treating acute myeloid leukemia and related conditions
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
WO2021118927A1 (en) 2019-12-13 2021-06-17 Insideoutbio, Inc. Methods and compositions for targeted delivery of nucleic acid therapeutics
CN114933569B (en) * 2022-04-07 2024-07-23 澳门科技大学 Sphingolipid compound, liposome containing sphingolipid compound and application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9000644D0 (en) * 1990-01-11 1990-03-14 Erba Carlo Spa New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
GB9216962D0 (en) * 1992-08-11 1992-09-23 Erba Carlo Spa Therapeutically active naphthalenesulfonic-pyrrolecarboxamido derivatives
GB9304589D0 (en) * 1993-03-05 1993-04-21 Erba Carlo Spa Biologically active ureido derivatives useful as antimetastic agents
GB9307948D0 (en) * 1993-04-16 1993-06-02 Erba Carlo Spa Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease
GB9403909D0 (en) * 1994-03-01 1994-04-20 Erba Carlo Spa Ureido derivatives of naphthalenephosphonic acids and process for their preparation

Also Published As

Publication number Publication date
CA2189358A1 (en) 1996-09-06
NO964610L (en) 1996-10-31
KR970702868A (en) 1997-06-10
GB9504065D0 (en) 1995-04-19
ZA961636B (en) 1996-09-06
EP0758339A1 (en) 1997-02-19
NO964610D0 (en) 1996-10-31
FI964331A0 (en) 1996-10-28
EA000006B1 (en) 1997-12-30
PL317094A1 (en) 1997-03-17
CN1148391A (en) 1997-04-23
HUP9603305A2 (en) 1997-08-28
MX9605089A (en) 1997-12-31
EA199600104A1 (en) 1997-09-30
JPH10504319A (en) 1998-04-28
IL117193A0 (en) 1996-06-18
AU4869896A (en) 1996-09-18
WO1996026950A1 (en) 1996-09-06
FI964331A (en) 1996-11-01
NZ302267A (en) 1997-10-24
AU696470B2 (en) 1998-09-10
HUP9603305A3 (en) 1998-01-28

Similar Documents

Publication Publication Date Title
AR002280A1 (en) A COMPOUND DERIVED FROM THE POLY-PIRROL-CARBOXAMIDONAPHTHALENIC ACID, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND A PROCEDURE TO IMPROVE THE SYSTEMIC BIOAVAILABILITY OF A BIOLOGICALLY ACTIVE COMPOUND.
UA41446C2 (en) Use of fumagilol or its derivatives for preparing drugs intended for treating intestinal infection and pharmaceutical composition
AR015524A1 (en) STABLE FORMULATION OF OXIPLATIN SOLUTION, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCESS FOR PREPARATION, PHARMACEUTICAL PRODUCT CONTAINING IT AND A METHOD FOR STABILIZING AN OXALIPLATIN SOLUTION.
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
HU9200823D0 (en) Process for the production of cyclical carbamide derivatives and medical preparations containing them as active agents
IL75337A (en) Polyenoic acids omega-substituted by a 4,5-dimethoxy-2-methyl-quinone or a 4,5-dimethoxy-2-methyl-phenyl group,process for the preparation thereof and pharmaceutical compositions containing the same
IL122401A0 (en) Anti-inflammatory compositions
HU9201258D0 (en) Process for the production of medical preparations for treating hiv infections and of their active agents
IL154210A0 (en) Methods and pharmaceutical compositions for healing wounds
SE8801513L (en) PHARMACEUTICAL COMPOSITION
UA35607C2 (en) oxazolidinonecarboxylic ACID derivatives, a process for the preparation thereof, pharmaceutical composition and a method for the preparation thereof
CA2256718A1 (en) Dihydrobenzopyran and related compounds useful as anti-inflammatory agents
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
DE3371627D1 (en) Acetylsalicylic acid thioesters, a process for their preparation and pharmaceutical compositions containing them
IT1260155B (en) THERAPEUTIC USE OF PHOSPHORYL-L-SERINE-N-ACYL-SPHINGOSINE
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
DE2963545D1 (en) Pharmaceutical composition containing all-e- or 13-z-7,8-dehydro-retinoic acid and process for its preparation
FR2440353A1 (en) NOVEL ARYLETHANOLS, PROCESSES FOR OBTAINING THEM AND THEIR USE AS A MEDICINAL PRODUCT
WO2001030338A8 (en) 6-methoxy-2-naphthylacetic acid prodrugs for treating inflammation
AU1400895A (en) 2,3-diaryl-1-benzopyrans for treating dermatitis
IE43872L (en) 2,9-dioxatricyclo [4.3.1.0(3,7)] decanes
DE3372772D1 (en) Quinazolinone derivatives, process for their preparation and their use in medicaments
DK8502611A (en)
DK0541726T3 (en) Growth factor compositions, preparation and application
ES8506614A1 (en) Derivatives of d-2-(6-methoxy-2-naphthyl)-propionic acid having therapeutical activity, process for their preparation and pharmaceutical compositions containing them.